Medpace Holdings, Inc. (MEDP) company profile
Close on Nov 17, 2026Market cap $18.27BP/E 36.2Yield –
About Medpace
Services-Commercial Physical & Biological Research, SIC 8731
Medpace Holdings, Inc. is a clinical contract research organization that provides outsourced clinical development services across Phase I through Phase IV trials. Its offerings serve biotechnology, pharmaceutical, and medical device companies, focusing especially on small and mid-sized biopharmaceutical developers. The company provides medical study design, trial execution via its proprietary ClinTrak software, patient recruitment, regulatory compliance, biometrics, pharmacovigilance, and quality assurance. Additionally, it provides specialized laboratory support through central, bioanalytical, and core imaging and cardiovascular facilities, alongside research clinics that evaluate therapeutics in healthy volunteers and targeted patient groups.
Medpace maintains an international presence with approximately 6,200 employees distributed across 46 countries worldwide. Its laboratory network spans locations in Cincinnati, Ohio; Leuven, Belgium; Shanghai, China; and Singapore. In addition, the company's dedicated bioanalytical laboratory and early-phase clinical trial facilities operate from its central research campus located in Cincinnati, Ohio, where key corporate activities are centered.
Summary of the business section of Medpace's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Medpace Holdings, Inc.
- Founded
- 1992
- Headquarters
- Cincinnati, OH
- Address
- 5375 Medpace Way 45227
- Phone
- (513) 579-9911
- Website
- medpace.com
- Employees
- 6,200, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Cincinnati, Ohio
Stock & identifiers
- Ticker
- MEDP
- Exchange
- Nasdaq
- IPO date
- Aug 11, 2016
- Shares outstanding
- 28M, Oct 16, 2026
- Public float
- $7.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1668397
- CUSIP
- 58506Q109
- ISIN
- US58506Q1094
- FIGI
- BBG0065B7K59
- Share class FIGI
- BBG0065B7K40
- LEI
- 549300H8TYEUVTW14A54
- EIN
- 32-0434904
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| August J. Troendle | President & CEO, Director | 5,071,244 |
| Stephen P. Ewald | General Counsel & Corp. Secy. | 19,098 |
| Susan E. Burwig | Exec. VP, Operations | 54,012 |
| Kevin M. Brady | CFO & Treasurer | 12,830 |
| Brad W. Hansman | Exec. VP, Operations | 697 |
| Jesse J. Geiger | President | 46,707 |
| Robert O. Kraft | Director | 987 |
| Cornelius P. McCarthy III | Director | 12,303 |
| Brian T. Carley | Director | 27,861 |
| Fred B. Davenport Jr | Director | 11,259 |
| Dani S. Zander | Director | – |
| Femida H. Gwadry-Sridhar | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $11.44M | $11.67M | $2.20M | $403 | $99 |
| FY2024 | $8.60M | $17.71M | $4.18M | $239 | $81 |
| FY2023 | $1.65M | $9.26M | $918.63K | $220 | $82 |
| FY2022 | $1.89M | $12.89M | $1.04M | $153 | $77 |
| FY2021 | $5.95M | $7.75M | $1.97M | $156 | $96 |
| FY2020 | $4.14M | $5.99M | $1.79M | $166 | $130 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| August J. Troendle Chief Executive Officer | $937.42K | $492.35K | $10.00M | $14.00K | $11.44M | +33% |
| Kevin M. Brady Chief Financial Officer and Treasurer | $459.70K | $172.45K | $1.00M | $14.00K | $1.65M | -53% |
| Jesse J. Geiger President | $641.67K | $240.70K | $1.50M | $14.00K | $2.40M | -49% |
| Susan E. Burwig Executive Vice President, Operations | $710.42K | $497.40K | $1.50M | $15.92K | $2.72M | -44% |
| Stephen P. Ewald General Counsel and Corporate Secretary | $591.51K | $414.15K | $1.00M | $14.00K | $2.02M | -45% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 11, 2016
- Offer price
- $23.00
- Securities offered
- 7,000,000
- Gross proceeds
- $161.00M
- Exchange
- Nasdaq
- First trading day
- Aug 11, 2016
- First-day close
- $27.79+20.8%
- Lock-up ends (est.)
- Feb 7, 2017
“The initial public offering price is $23.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025 we had approximately 6,200 employees located across 46 countries.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 11, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 9, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?